Overview
Dienaba Kasse practices practicing medicine in Conakry, Guinea.
Their clinical expertise encompasses Inflammatory Breast Cancer, Ebola Virus Disease, and Viral Hemorrhagic Fever.
They are actively involved in clinical research, co-authoring 8 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Dienaba Kasse
Is Dienaba Kasse a top-rated expert for Inflammatory Breast Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Dienaba Kasse is classified as an Experienced expert for Inflammatory Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Dienaba Kasse participate in research or clinical trials?
Yes. Dienaba Kasse has published 8 articles and abstracts on conditions like Inflammatory Breast Cancer. You can view a list of Dienaba Kasse's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Ebola Virus DiseaseKasse isExperienced. Learn about Ebola Virus Disease.
- Inflammatory Breast CancerKasse isExperienced. Learn about Inflammatory Breast Cancer.
- Viral Hemorrhagic FeverKasse isExperienced. Learn about Viral Hemorrhagic Fever.